LIAN Live signaler | Maksimer profitt med Getagraph.com

SELG 107077 min ago

@ $4.83

Utstedt: 14 feb 2024 @ 15:35

Avkastning: -93.39%

Live Chart Being Loaded With Signals

Commentary (4 apr 2024 @ 22:00):

Stats
Dagens volum	2.48M
Gjennomsnittsvolum	959 835
Markedsverdi	34.47M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.00600 (1.80%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Gu Ehong	Sell	1 731	Ordinary Shares
2024-04-09	Gu Ehong	Sell	17 889	Ordinary Shares
2024-02-15	Poukalov Konstantin	Buy	36 300	Ordinary Shares
2024-02-15	Poukalov Konstantin	Sell	19 218	Ordinary Shares
2024-02-15	Poukalov Konstantin	Sell	36 300	Stock Option (Right to Buy)

INSIDER POWER
70.94
Last 79 transactions
Buy: 50 859 501 \| Sell: 7 434 951

Volum Korrelasjon

Lang: 0.35 (neutral)

Kort: 0.36 (neutral)

Signal:(47.977) Neutral

LianBio Korrelasjon

10 Mest positive korrelasjoner
IPHA	0.872
PRDS	0.853
ORIC	0.841
AMRB	0.836
CHRS	0.811
BGNE	0.801

10 Mest negative korrelasjoner
EMBC	-0.83

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

LianBio Korrelasjon - Valuta/Råvare

-0.21
( neutral )

-0.56
( weak negative )

0.00
( neutral )

0.64
( weak )

LianBio Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$-1.00M (0.00 %)
EPS:	$-1.020

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.00M (0.00 %)
EPS:	$-1.020

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.03

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.450

Financial Reports:

No articles found.

LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.